Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 7/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728834 | 0.82 | ESR2 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL7028198 | 0.77 | CA1 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL6936222 | 0.77 | CA1 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3709873 | 0.77 | GRIA4 (0.46) | — | |
| SCHEMBL6936031 | 0.76 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL29024298 | 0.76 | CA1 (0.60) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3179213 | 0.75 | ESR2 (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL338102 | 0.75 | GRIA4 (0.55) | CA1CA2CA9CA12CA3 | |
| SCHEMBL6936218 | 0.75 | GRIA4 (0.55) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3828099 | 0.74 | TAAR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | CA1 1037/4885CA2 1756/4885CA9 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.